Smallpox - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Smallpox - Pipeline Review, H1 2019’, provides an overview of the Smallpox pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Smallpox

- The report reviews pipeline therapeutics for Smallpox by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Smallpox therapeutics and enlists all their major and minor projects

- The report assesses Smallpox therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Smallpox

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Smallpox

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bavarian Nordic A/S

BioFactura Inc

CEL-SCI Corp

Chimerix Inc

CJ HealthCare Corp

EpiVax Inc

Fox Chase Chemical Diversity Center Inc

SIGA Technologies Inc

Tonix ...

Bavarian Nordic A/S

BioFactura Inc

CEL-SCI Corp

Chimerix Inc

CJ HealthCare Corp

EpiVax Inc

Fox Chase Chemical Diversity Center Inc

SIGA Technologies Inc

Tonix Pharmaceuticals Holding Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Smallpox - Overview

Smallpox - Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Smallpox - Overview

Smallpox - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Smallpox - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smallpox - Companies Involved in Therapeutics Development

Bavarian Nordic A/S

BioFactura Inc

CEL-SCI Corp

Chimerix Inc

CJ HealthCare Corp

EpiVax Inc

Fox Chase Chemical Diversity Center Inc

SIGA Technologies Inc

Tonix Pharmaceuticals Holding Corp

Smallpox - Drug Profiles

24a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brincidofovir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-40011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Smallpox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox [ankara] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tecovirimat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIR-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smallpox - Dormant Projects

Smallpox - Discontinued Products

Smallpox - Product Development Milestones

Featured News & Press Releases

Jan 18, 2019: Bavarian Nordic announces exercise of USD 44 million option by the U.S. Government under contract for freeze-dried MVA-BN Smallpox vaccine

Dec 21, 2018: Bavarian Nordic announces FDA acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine

Nov 01, 2018: SIGA announces Priority Review Voucher transaction totaling $80 million

Oct 05, 2018: Chimerix presents results from multiple ascending dose study of IV Brincidofovir at IDWeek

Oct 04, 2018: Landmark adVance study shows adenovirus burden correlates with mortality in pediatric allogeneic hematopoietic cell transplant recipients

Sep 19, 2018: Bavarian Nordic delivers Smallpox Vaccine to England in response to current Monkeypox Cases

Sep 10, 2018: SIGA Technologies awarded BARDA contract for TPOXX

Aug 21, 2018: Importance of Smallpox vaccination highlighted in biopreparedness exercise

Aug 09, 2018: Bavarian Nordic Granted EUR 30 Million loan from The European Investment Bank

Jul 13, 2018: FDA approves TPOXX as first drug to treat smallpox

Jul 05, 2018: Pivotal Trial Data for SIGA Technologies’ Oral TPOXX Published in the New England Journal of Medicine

Jun 07, 2018: Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox

Jun 05, 2018: Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)

May 31, 2018: SIGA to Present at the Jefferies Global Healthcare Conference on June 8, 2018

May 01, 2018: SIGA Technologies Announces Favorable Outcome of Advisory Committee In Support of TPOXX

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Smallpox, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Smallpox, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Smallpox - Pipeline by Bavarian Nordic A/S, H1 2019

Smallpox - Pipeline by BioFactura Inc, H1 2019

Smallpox - Pipeline by CEL-SCI Corp, H1 2019

Smallpox - Pipeline by Chimerix Inc, H1 2019

Smallpox - Pipeline by CJ HealthCare Corp, H1 2019

Smallpox - Pipeline by EpiVax Inc, H1 2019

Smallpox - Pipeline by Fox Chase Chemical Diversity Center Inc, H1 2019

Smallpox - Pipeline by SIGA Technologies Inc, H1 2019

Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2019

Smallpox - Dormant Projects, H1 2019

Smallpox - Dormant Projects, H1 2019 (Contd..1), H1 2019

Smallpox - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Smallpox, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by ...

List of Figures

Number of Products under Development for Smallpox, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports